Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

Clinical trial NCT04005352 · COMPLETED

Trial details

NCT number: NCT04005352
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Age-related Macular Degeneration

Start date: 2019-09-25
Primary completion: 2022-09-09
Enrollment: 734

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.